|
|
Vaccine Detail
|
Recombinant Human Fusion Protein L19TNFalpha Vaccine |
| Vaccine Information |
- Vaccine Name: Recombinant Human Fusion Protein L19TNFalpha Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007070
- Type: Other
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- tnf-alpha
gene engineering:
- Type: Recombinant protein preparation
- Description: (Halin et al., 2003)
- Detailed Gene Information: Click Here.
- Preparation: ILT was constructed by performing a PCR assembly between the gene encoding the p40-p35 fusion (IL-12 in a single polypeptide chain format), amplified from IL-12-L19 (15) and the gene encoding L19-TNF-α (Halin et al., 2003).
- Description: This is for Colon Cancer (NCT01253837). An immunocytokine consisting of human pro-inflammatory cytokine tumor necrosis factor alpha (TNFalpha) fused to a human single-chain variable fragment (scFv) directed against the extra-domain B (ED-B) of fibronectin (L19), with potential immunopotentiating and antineoplastic activities. The L19 moiety of recombinant human fusion protein L19TNFalpha binds to the ED-B domain of fibronectin on tumor cells in the tumor neovasculature. In turn, the TNFalpha moiety may locally induce an immune response against ED-B fibronectin-expressing tumor cells and may specifically decrease the proliferation of ED-B-expressing tumor cells. ED-B is predominantly expressed during angiogenesis and tumor growth (NCIT_C94210).
|
| Host Response |
|
|
| References |
Halin et al., 2003: Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, Zardi L, Neri D. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer research. 2003; 63(12); 3202-3210. [PubMed: 12810649].
NCIT_C94210: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94210]
NCT01253837: [https://clinicaltrials.gov/ct2/show/NCT01253837]
|
|
